Bristol-Myers Squibb Co Stock Forecast for 2023 - 2025 - 2030
Updated on 09/26/2023
Bristol-Myers Squibb Co Stock Forecast and Price Target
If the average 2023 price target of $83.00 recently set by thridteen prominent experts for Bristol-Myers Squibb Co is met, there would be a potential upside of approximately 40.3% from the last closing price in September, 2023. The high estimate is $95.00, and the low is $60.00. If you're looking for information on Bristol-Myers Squibb Co stock, consider checking out the forecasts for comparable firms such as NasdaqGS:REGN.
40.30% Upside
Bristol-Myers Squibb Co Fair Value Forecast for 2023 - 2025 - 2030
In the last two years, Bristol-Myers Squibb Co's Price has grown, rising from $47.79 to $76.53 – a growth of 60.13%. In the next year, analysts believe that Fair Value will reach $83.86 – an increase of 9.59%. By 2030, professionals predict that Bristol-Myers Squibb Co's Fair Value will decrease by 8.79%, to $69.80.
| Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|---|
| LLY Stock Forecast | Eli Lilly & Co | Outperform |
14
|
$552.32 | Buy/Sell | $333.19 | -27.58% |
| JNJ Stock Forecast | Johnson & Johnson | Outperform |
10
|
$160.26 | Buy/Sell | $179.95 | 12.63% |
| PFE Stock Forecast | Pfizer Inc | Outperform |
3
|
$32.98 | Buy/Sell | $44.13 | 59.64% |
| MRK Stock Forecast | Merck | Outperform |
5
|
$105.84 | Buy/Sell | $99.57 | 11.49% |
| VRTX Stock Forecast | Vertex Pharmaceuticals Inc | Outperform |
13
|
$350.67 | Buy/Sell | $384.26 | -7.04% |
Bristol-Myers Squibb Co Revenue Forecast for 2023 - 2025 - 2030
In the last three years, Bristol-Myers Squibb Co's Revenue has grown, rising from $26.15B to $46.16B – a growth of 76.55%. In the next year, analysts believe that Revenue will reach $48.66B – an increase of 5.42%. By 2030, professionals predict that Bristol-Myers Squibb Co's Revenue will decrease by 20.06%, to $36.90B.
| Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|---|
| ZTS Stock Forecast | Zoetis Inc | Outperform |
18
|
$177.72 | Buy/Sell | $209.70 | 15.35% |
| REGN Stock Forecast | Regeneron Pharmaceuticals Inc | Outperform |
2
|
$834.64 | Buy/Sell | $796.73 | -6.31% |
| BAX Stock Forecast | Baxter International Inc | Outperform |
17
|
$37.50 | Buy/Sell | $60.73 | 54.67% |
.jpg)
Bristol-Myers Squibb Co Dividend per Share Forecast for 2023 - 2025 - 2030
Bristol-Myers Squibb Co's Dividend per Share has grown In the last three years, rising from $1.68 to $2.28 – a growth of 35.71%. For the following year, the 10 analysts predict that Bristol-Myers Squibb Co's Dividend per Share will drop by 1.32%, reaching $2.25. In 2030, the professionals' prediction is that BMY's Dividend per Share will decrease by 7.89%, reaching $2.10.
| Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|---|
| ALNY Stock Forecast | Alnylam Pharmaceuticals Inc | Outperform |
7
|
$170.77 | Buy/Sell | $244.18 | 46.98% |
| VTRS Stock Forecast | Viatris Inc | Hold |
8
|
$9.71 | Buy/Sell | $13.70 | 39.03% |
| UTHR Stock Forecast | United Therapeutics Corp | Outperform |
12
|
$224.06 | Buy/Sell | $280.69 | 31.66% |
Bristol-Myers Squibb Co Free Cash Flow Forecast for 2023 - 2025 - 2030
In the last three years, Bristol-Myers Squibb Co's Free Cash Flow has grown by 197613122.50%, rising from $7.37B to $14572.00T. The next year, 7 experts forecast that Bristol-Myers Squibb Co's Free Cash Flow will decrease by 100.00%, reaching $19.68B. In 2030, professionals predict that Bristol-Myers Squibb Co's Free Cash Flow will decrease by 100.00%, reaching $14.89B.
| Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|---|
| CTLT Stock Forecast | Catalent Inc | Hold |
15
|
$45.82 | Buy/Sell | $83.92 | 59.32% |
| IONS Stock Forecast | Ionis Pharmaceuticals Inc | Outperform |
9
|
$42.67 | Buy/Sell | $52.42 | 17.18% |
| BCPC Stock Forecast | Balchem | Outperform |
18
|
$126.67 | Buy/Sell | $163.67 | 29.47% |
Bristol-Myers Squibb Co Net Income Forecast for 2023 - 2025 - 2030
Bristol-Myers Squibb Co's Net Income has seen impressive growth In the last three years, rising from $3.44B to $6.35B – a growth of 84.50%. In the next year, analysts believe that Net Income will reach $17.26B – an increase of 172.08%. For the next eight years, the forecast is for Net Income to grow by 109.51%.
| Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|---|
| NEOG Stock Forecast | Neogen | Hold |
16
|
$19.48 | Buy/Sell | $37.00 | 30.90% |
| CYTK Stock Forecast | Cytokinetics Inc | Outperform |
10
|
$30.00 | Buy/Sell | $62.67 | 100.00% |
| TGTX Stock Forecast | TG Therapeutics | Outperform |
9
|
$8.97 | Buy/Sell | $73.38 | 111.82% |
Bristol-Myers Squibb Co EBITDA Forecast for 2023 - 2025 - 2030
In the last three years, Bristol-Myers Squibb Co's EBITDA has grown, moving from $6.30B to $19.92B – an increase of 216.34%. In the next year, analysts predict that EBITDA will jump to $21.50B – up 7.91% from the current level. By 2030, professionals believe that Bristol-Myers Squibb Co's EBITDA will have decreased by 30.31%, falling to $13.89B.
| Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|---|
| INDV Stock Forecast | Indivior PLC | Buy |
14
|
£21.51 | Buy/Sell | £3.79 | -77.96% |
| PCRX Stock Forecast | Pacira BioSciences | Outperform |
16
|
$32.82 | Buy/Sell | $79.67 | 137.66% |
| CORT Stock Forecast | Corcept Therapeutics | Outperform |
16
|
$32.32 | Buy/Sell | $0.00 | -8.73% |
Bristol-Myers Squibb Co EBIT Forecast for 2023 - 2025 - 2030
In the last two years, Bristol-Myers Squibb Co's EBIT has seen an increase, rising from $4.58B to $9.82B. This represents a growth of 114.59%. Analysts predict that Bristol-Myers Squibb Co's EBIT will increase in the upcoming year, reaching $20.34B. This would represent an increase of 107.11%. Over the next eight years, experts predict that Bristol-Myers Squibb Co's EBIT will grow at a rate of 54.90%.
| Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|---|
| AMPH Stock Forecast | Amphastar Pharmaceuticals | Outperform |
14
|
$45.96 | Buy/Sell | $41.00 | -4.26% |
| IRWD Stock Forecast | Ironwood Pharmaceuticals | Hold |
14
|
$8.53 | Buy/Sell | $12.60 | 46.54% |
| SUPN Stock Forecast | Supernus Pharmaceuticals | Outperform |
16
|
$30.06 | Buy/Sell | $35.50 | 13.11% |
Bristol-Myers Squibb Co EPS Price Prediction Forecast for 2023 - 2025 - 2030
In the last two years, Bristol-Myers Squibb Co's EPS has grown, rising from $4.69 to $7.51 – a growth of 60.13%. In the next year, analysts believe that EPS will reach $8.23 – an increase of 9.59%. By 2030, professionals predict that Bristol-Myers Squibb Co's EPS will decrease by 8.79%, to $6.85.
| Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|---|
| LGND Stock Forecast | Ligand Pharmaceuticals | Outperform |
14
|
$58.86 | Buy/Sell | $195.43 | 169.28% |
| MDGL Stock Forecast | Madrigal Pharmaceuticals | Outperform |
4
|
$150.96 | Buy/Sell | $170.08 | 15.92% |
| USNA Stock Forecast | USANA Health Sciences | Hold |
14
|
$59.75 | Buy/Sell | $104.00 | -4.60% |
Site Navigation
.jpg)